Novel selective and metabolically stable inhibitors of anandamide cellular uptake

Biochemical Pharmacology

Volumn 65, Issue 9, 2003, Pages 1473-1481

  Ortar, Giorgio ^a,b   Ligresti, Alessia ^b   De Petrocellis, Luciano ^b   Morera, Enrico ^a,b   Di Marzo, Vincenzo ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CNR   (Italy)

Author keywords

Cannabinoid; Endocannabinoid; FAAH; Receptor; Transport; VR1

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ANANDAMIDE; ARACHIDONOYL N' (4 HYDROXY 3 METHOXYBENZYL)HYDRAZINE; AROMATIC COMPOUND; CANNABINOID RECEPTOR; FATTY ACID AMIDASE; HYDRAZINE DERIVATIVE; N OLEOYLETHANOLAMINE; OLEOYL N' (4 HYDROXY 3 METHOXYBENZYL)HYDRAZINE; RECEPTOR SUBTYPE; RIMONABANT; UNCLASSIFIED DRUG; VANILLOID RECEPTOR;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BIOASSAY; BRAIN HOMOGENATE; BRAIN MEMBRANE; CALCIUM CELL LEVEL; CONTROLLED STUDY; DRUG INHIBITION; DRUG SELECTIVITY; DRUG UPTAKE; EMBRYO; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HYDROLYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; RAT; SIGNAL TRANSDUCTION;

EID: 0037542450     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00109-6     Document Type: Article

References (44)

1. Pertwee R.G. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther. 74:1997;129-180.
2. Di Marzo V. 'Endocannabinoids' and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. Biochim. Biophys. Acta. 1392:1998;53-75.
3. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
4. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., Gopher A., Almog S., Martin B.R., Compton D.R., Pertwee R.G., Griffin G., Bayewitch M., Barg J., Vogel Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50:1995;83-90.
5. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., Yamashita A., Waku K. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215:1995;89-97.
6. Hanus L., Abu-Lafi S., Fride E., Breuer A., Vogel Z., Shalev D.E., Kustanovich I., Mechoulam R. 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl. Acad. Sci. U.S.A. 98:2001;3662-3665.
7. Porter A.C., Sauer J.M., Knierman M.D., Becker G.W., Berna M.J., Bao J., Nomikos G.G., Carter P., P F., Leese A.B., Felder C.C. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J. Pharmacol. Exp. Ther. 301:2002;1020-1024.
8. Sugiura T., Kobayashi Y., Oka S., Waku K. Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. Prostaglandins Leukot. Essent. Fatty Acids. 66:2002;173-192.
9. Fowler C.J., Jacobsson S.O. Cellular transport of anandamide, 2-arachidonoylglycerol and palmitoylethanolamide - targets for drug development? Prostaglandins Leukot. Essent. Fatty Acids. 66:2002;193-200.
10. Ueda N., Kurahashi Y., Yamamoto S., Tokunaga T. Partial purification and characterization of the porcine brain enzyme hydrolyzing and synthesizing anandamide. J. Biol. Chem. 270:1995;23823-23827.
11. Cravatt B.F., Giang D.K., Mayfield S.P., Boger D.L., Lerner R.A., Gilula N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 384:1996;83-87.
12. Goparaju S.K., Ueda N., Yamaguchi H., Yamamoto S. Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. FEBS Lett. 422:1998;69-73.
13. Di Marzo V., Bisogno T., De Petrocellis L., Melck D., Orlando P., Wagner J.A., Kunos G. Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur. J. Biochem. 264:1999;258-267.
14. Fezza F., Bisogno T., Minassi A., Appendino G., Mechoulam R., Di Marzo V. Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Lett. 513:2002;294-298.
15. Di Marzo V., Bisogno T., Sugiura T., Melck D., De Petrocellis L. The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide. Biochem. J. 331:1998;15-19.
16. Deutsch D.G., Glaser S.T., Howell J.M., Kunz J.S., Puffenbarger R.A., Hillard C.J., Abumrad N. The cellular uptake of anandamide is coupled to its breakdown by fatty-acid amide hydrolase. J. Biol. Chem. 276:2001;6967-6973.
17. Jarrahian A., Manna S., Edgemond W.S., Campbell W.B., Hillard C.J. Structure-activity relationships among N-arachidonylethanolamine (Anandamide) head group analogues for the anandamide transporter. J. Neurochem. 74:2000;2597-2606.
18. Maccarrone M., Bari M., Lorenzon T., Bisogno T., Di Marzo V., Finazzi-Agro' A. Anandamide uptake by human endothelial cells and its regulation by nitric oxide. J. Biol. Chem. 275:2000;13484-13492.
19. Maccarrone M., van der Stelt M., Rossi A., Veldink G.A., Vliegenthart J.F., Finazzi-Agro' A. Anandamide hydrolysis by human cells in culture and brain. J. Biol. Chem. 273:1998;32332-32339.
20. Melck D., Bisogno T., De Petrocellis L., Chuang H., Julius D., Bifulco M., Di Marzo V. Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. Biochem. Biophys. Res. Commun. 262:1999;275-284.
21. Di Marzo V., Griffin G., De Petrocellis L., Brandi I., Bisogno T., Williams W., Grier M.C., Kulasegram S., Mahadevan A., Razdan R.K., Martin B.R. A structure/activity relationship study on arvanil, an endocannabinoid and vanilloid hybrid. J. Pharmacol. Exp. Ther. 300:2002;984-991.
22. Di Marzo V., De Petrocellis L., Fezza F., Ligresti A., Bisogno T. Anandamide receptors. Prostaglandins Leukot. Essent. Fatty Acids. 66:2002;377-391.
23. Szallasi A., Blumberg P.M. Vanilloid (Capsaicin) receptors and mechanisms. Pharmacol. Rev. 51:1999;159-212.
24. Mezey E., Toth Z.E., Cortright D.N., Arzubi M.K., Krause J.E., Elde R., Guo A., Blumberg P.M., Szallasi A. Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc. Natl. Acad Sci. U.S.A. 97:2000;3655-3660.
25. Di Marzo V., Bisogno T., Melck D., Ross R., Brockie H., Stevenson L., Pertwee R., De Petrocellis L. Interactions between synthetic vanilloids and the endogenous cannabinoid system. FEBS Lett. 436:1998;449-454.
26. De Petrocellis L., Bisogno T., Davis J.B., Pertwee R.G., Di Marzo V. Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett. 483:2000;52-56.
27. Zygmunt P.M., Chuang H., Movahed P., Julius D., Hogestatt E.D. The anandamide transport inhibitor AM404 activates vanilloid receptors. Eur. J. Pharmacol. 396:2000;39-42.
28. Di Marzo V., Bisogno T., De Petrocellis L., Brandi I., Jefferson R.G., Winckler R.L., Davis J.B., Dasse O., Mahadevan A., Razdan R.K., Martin B.R. Highly selective CB(1) cannabinoid receptor ligands and novel CB(1)/VR(1) vanilloid receptor "hybrid" ligands. Biochem. Biophys. Res. Commun. 281:2001;444-451.
29. Beltramo M., Stella N., Calignano A., Lin S.Y., Makriyannis A., Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science. 277:1997;1094-1097.
30. Piomelli D., Beltramo M., Glasnapp S., Lin S.Y., Goutopoulos A., Xie X.Q., Makriyannis A. Structural determinants for recognition and translocation by the anandamide transporter. Proc. Natl. Acad. Sci. U.S.A. 96:1999;5802-5807.
31. Ross R.A., Gibson T.M., Brockie H.C., Leslie M., Pashmi G., Craib S.J., Di Marzo V., Pertwee R.G. Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. Br. J. Pharmacol. 132:2001;631-640.
32. Lopez-Rodriguez M.L., Viso A., Ortega-Gutierrez S., Lastres-Becker I., Gonzalez S., Fernandez-Ruiz J., Ramos J.A. Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors. J. Med. Chem. 44:2001;4505-4508.
33. Hillard C.J., Edgemond W.S., Jarrahian A., Campbell W.B. Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. J. Neurochem. 69:1997;631-638.
34. Wu P-L, Peng S-Y, Magrath J. 1-Acyl-2-alkylhydrazines by the reduction of acylhydrazones. Synthesis 1995;435-8.
35. Grundon MF, Scott MD. The reaction of hydrazones and related compounds with strong base. Part II. Nitriles from phenylhydrazones. J Chem Soc 1964;5674-9.
36. Bisogno T., Maurelli S., Melck D., De Petrocellis L., Di Marzo V. Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J. Biol. Chem. 272:1997;3315-3323.
37. Maurelli S., Bisogno T., De Petrocellis L., Di Luccia A., Marino G., Di Marzo V. Two novel classes of neuroactive fatty acid amides are substrates for mouse neuroblastoma 'anandamide amidohydrolase'. FEBS Lett. 377:1995;82-86.
38. Lopez-Rodriguez M.L., Viso A., Ortega-Gutierrez S., Fernandez-Ruiz J., Ramos J.A. Endocannabinoid transporter inhibitors. Curr. Med. Chem.-CNS Agents. 2:2002;129-141.
39. Abadji V., Lin S., Taha G., Griffin G., Stevenson L.A., Pertwee R.G., Makriyannis A. (R)-Methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J. Med. Chem. 37:1994;1889-1893.
40. Palmer S.L., Khanolkar A.D., Makriyannis A. Natural and synthetic endocannabinoids and their structure-activity relationships. Curr. Pharm. Des. 6:2000;1381-1397.
41. Bisogno T., Melck D., Bobrov M.Yu., Gretskaya N.M., Bezuglov V.V., De Petrocellis L., Di Marzo V. N-Acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem. J. 351:2000;817-824.
42. Huang S.M., Bisogno T., Trevisani M., Al-Hayani A., De Petrocellis L., Fezza F., Tognetto M., Petros T.J., Krey J.F., Chu C.J., Miller J.D., Davies S.N., Geppetti P., Walker J.M., Di Marzo V. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc. Natl. Acad. Sci. U.S.A. 99:2002;8400-8405.
43. Brooks J.W., Pryce G., Bisogno T., Jaggar S.I., Hankey D.J., Brown P., Bridges D., Ledent C., Bifulco M., Rice A.S., Di Marzo V., Baker D. Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptors. Eur. J. Pharmacol. 439:2002;83-92.
44. Edgemond W.S., Campbell W.B., Hillard C.J. The binding of novel phenolic derivatives of anandamide to brain cannabinoid receptors. Prostaglandins Leukot. Essent. Fatty Acids. 52:1995;83-86.